NasdaqGM - Delayed Quote USD

Cartesian Therapeutics, Inc. (RNAC)

24.75

+3.30

(+15.38%)

At close: May 14 at 4:00 PM EDT

24.75

0.00

(0.00%)

After hours: May 14 at 4:20 PM EDT

Key Events

Loading Chart for RNAC

9/21 12:03 PM

DELL

Previous Close 21.45
Open 21.59
Bid 24.41 x 100
Ask 25.00 x 100
Day's Range 21.59 - 25.10
52 Week Range 11.66 - 42.60
Volume 164,430
Avg. Volume 68,568
Market Cap (intraday) 440.453M
Beta (5Y Monthly) --
PE Ratio (TTM) --
EPS (TTM) --
Earnings Date May 8, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 51.00

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

www.cartesiantherapeutics.com

37

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RNAC

19.74%

S&P 500

10.00%

1-Year Return

RNAC

28.88%

S&P 500

27.22%

3-Year Return

RNAC

71.84%

S&P 500

27.58%

5-Year Return

RNAC

64.13%

S&P 500

86.59%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Cartesian Therapeutics, Inc.

24.75

+15.38%

Mkt Cap 440.453M

Industry Biotechnology

31.55

+2.97%

Mkt Cap 409.528M

Industry Biotechnology

2.6100

-1.14%

Mkt Cap 127.001M

Industry Biotechnology

TScan Therapeutics, Inc.

8.99

+12.23%

Mkt Cap 436.79M

Industry Biotechnology

Rigel Pharmaceuticals, Inc.

0.9475

-3.53%

Mkt Cap 172.284M

Industry Biotechnology

Eledon Pharmaceuticals, Inc.

2.3400

+6.85%

Mkt Cap 88.741M

Industry Biotechnology

Kezar Life Sciences, Inc.

0.7895

+5.62%

Mkt Cap 57.477M

Industry Biotechnology

Elevation Oncology, Inc.

3.5600

+0.56%

Mkt Cap 194.512M

Industry Biotechnology

Sensei Biotherapeutics, Inc.

1.5100

-3.82%

Mkt Cap 39.377M

Industry Biotechnology

0.1759

-6.44%

Mkt Cap 5.415M

Industry Biotechnology

CG Oncology, Inc.

27.32

+5.73%

Mkt Cap 1.821B

Industry Biotechnology

Valuation Measures

As of 5/13/2024

Market Cap

381.73M
Enterprise Value

288.76M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

4.34
Price/Book (mrq)

--
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

--
Return on Equity (ttm)

--
Revenue (ttm)

25.91M
Net Income Avi to Common (ttm)

-292.42M
Diluted EPS (ttm)

--

Balance Sheet and Cash Flow

Total Cash (mrq)

103.42M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

--

RNAC does not have Company Insights

CARM Carisma Therapeutics, Inc.

1.4600

-1.35%

TSBX Turnstone Biologics Corp.

2.8700

-5.28%

SGMT Sagimet Biosciences Inc.

4.3800

+3.30%

TRML Tourmaline Bio, Inc.

14.42

-0.14%

ZURA Zura Bio Limited

5.16

+7.72%

ZVRA Zevra Therapeutics, Inc.

4.8000

-1.84%

APLM Apollomics, Inc.

0.3550

+3.50%

ACRV Acrivon Therapeutics, Inc.

8.36

-1.42%

VIGL Vigil Neuroscience, Inc.

3.6600

+0.27%

SLRN Acelyrin, Inc.

4.7300

+0.85%

VINC Vincerx Pharma, Inc.

0.7646

+1.18%

DNTH Dianthus Therapeutics, Inc.

27.94

+7.42%

ALGS Aligos Therapeutics, Inc.

0.6915

+1.01%

SYRE Spyre Therapeutics, Inc.

39.29

+6.19%

MLYS Mineralys Therapeutics, Inc.

13.06

+1.01%

NMRA Neumora Therapeutics, Inc.

9.58

+6.92%